Formula Growth Ltd. Acquires Shares of 11,991 Insulet Corporation $PODD

Formula Growth Ltd. acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 11,991 shares of the medical instruments supplier’s stock, valued at approximately $1,826,000.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Insulet during the second quarter worth about $1,018,582,000. Norges Bank acquired a new stake in Insulet in the fourth quarter valued at about $300,794,000. Arrowstreet Capital Limited Partnership boosted its holdings in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Man Group plc purchased a new stake in Insulet in the 2nd quarter valued at approximately $78,746,000. Finally, Bank of America Corp DE acquired a new position in Insulet during the 2nd quarter worth approximately $64,921,000.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on PODD shares. Barclays cut their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Evercore set a $180.00 price objective on Insulet in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft started coverage on Insulet in a report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price objective on the stock. William Blair assumed coverage on Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. Finally, Weiss Ratings downgraded Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $195.40.

Insulet Price Performance

PODD stock opened at $143.41 on Friday. The firm has a 50 day moving average of $154.47 and a 200-day moving average of $181.40. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.95 billion, a price-to-earnings ratio of 26.81, a PEG ratio of 1.13 and a beta of 1.10.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s quarterly revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.